Der selektive Tyrosinkinase-Inhibitor Imatinib (STI571) bei hämatologischen und onkologischen Erkrankungen

A. Hochhaus

doi:10.1055/s-2002-20427

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2002; 127(9): 451-456
DOI: 10.1055/s-2002-20427

Übersichten

Der selektive Tyrosinkinase-Inhibitor Imatinib (STI571) bei hämatologischen und onkologischen Erkrankungen

Selective tyrosinekinase inhibitor imatinib (STI571) in haematological and oncological diseaseA. Hochhaus

III. Medizinische Universitätsklinik (Direktor: Prof. Dr. R. Hehlmann), Fakultät für Klinische Medizin Mannheim der Universität Heidelberg

Abstract

Full Text

References

Literatur

1 Apperley J F, Schultheis B, Chase A. et al . Chronic myeloproliferative diseases with t(5;12) and a PDGFRb fusion gene: Complete cytogenetic remissions on STI571. Blood. 2001; 98 (Suppl 1) 726a
2 Barthe C, Cony-Makhoul P, Melo J V, Reiffers J, Mahon F X. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001; 293 2163a
3 Beham Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Hofler G, Haas O A, Linkesch W. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood. 2002; 99 381-383
4 Brouard M, Saurat J H. Cutaneous reactions to STI571. N Engl J Med. 2001; 345 618-619
5 Buchdunger E, Cioffi C L, Law N, Stover D, Ohno-Jones S, Druker B J, Lydon N B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000; 295 139-145
6 Deininger M WN, Goldman J M, Lydon N, Melo J V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997; 90 3691-3698
7 Druker B J, Kantarjian H M, Talpaz M, Paquette R, Mauro M J, Rosamilia M, Zoellner U, Resta D, Capdeville R, Sawyers C L. A phase I study of Gleevec (imatinib mesylate) administered concomitantly with cytosine arabinoside (Ara-C) in patients with Philadelphia positive chronic myeloid leukemia (CML). Blood. 2001; 98 (Suppl 1) 845a-846a
8 Druker B J, Lydon N B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000; 105 3-7
9 Druker B J, Sawyers C L, Kantarjian H, Resta D J, Fernandez Reese S, Ford J M, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344 1038-1042
10 Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, Lydon N B, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers C L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344 1031-1037
11 Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, Zimmermann J, Lydon N B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Medic. 1996; 2 561-566
12 Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Piotelli P, Pogliani E, Corneo G, Formelli F, D’Incalci M. Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571. J Natl Cancer Inst. 2000; 92 1641-1650
13 Gambacorti-Passerini C, le C outre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo G M, Belotti D, Pogliani E, Lydon N B. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Diseases. 1997; 23 380-394
14 Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, Sawyers C L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293 876-880
15 Hehlmann R, Hochhaus A. Evidenzbasierte Therapie der chronischen myeloischen Leukämie. Dtsch Ärztebl. 2001; 98 A1834-A1837
16 Heinrich M C, Griffith D J, Druker B J, Wait C L, Ott K A, Zigler A J. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood. 2000; 96 925-932
17 Hochhaus A, Kreil S, Corbin A, La Rosée P, Lahaye T, Berger U, Cross N CP, Linkesch W, Druker B J, Hehlmann R. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001; 293 2163a
18 Joensuu H, Roberts P J, Sarlomo-Rikala M, Andersson L C, Tervahartiala P, Tuveson D, Silberman S L, Capdeville R, Dimitrijevic S, Druker B, Demetri G D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001; 344 1052-1056
19 Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001; 97 1999-2007
20 Kantarjian H M, Sawyers C L, Hochhaus A, Guilhot F, Schiffer C A, Deininger M W, Gambacorti-Passerini C, Stone R M, Goldman J, Fischer T, Rosamilia M, Zoellner U, Resta D, Capdeville R, Druker B J. GleevecTM (Imatinib mesylate) induced hematologic and cytogenetic responses confirmed and expanded in patients with chronic myeloid leukemia (CML) - A phase II study update. Blood. 2001; 98 (Suppl 1) 845a
21 Kilic T, Alberta J A, Zdunek P R, Acar M, Iannarelli P, O’Reilly T, Buchdunger E, Black P M, Stiles C. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Research. 2000; 60 5143-5150
22 Kreil S, Müller M C, Lahaye T, La Rosée P, Corbin A M, Schoch C, Cross N CP, Berger U, Rieder H, Druker B J, Gschaidmeier H, Hehlmann R, Hochhaus A. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. Blood. 2001; 98 (Suppl1) 435a
23 Krystal G W, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000; 6 3319-3326
24 Mahon F X, Deininger M WN, Schultheis B, Chabrol J, Reiffers J, Golfdman J M, Melo J V. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000; 96 1070-1079
25 Merx K, Kreil S, Lahaye T, Müller M C, Paschka P, Schoch C, Weisser A, Kuhn C, Landmann T, Gschaidmeier H, Berger U, Hehlmann R, Hochhaus A. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response to STI571 in chronic phase CML patients. Blood. 2001; 98 (Suppl 1) 846a-847a
26 O’Brien S, Vallance S E, Craddock C, Holyoake T L, Goldman J M. the UK PISCES Group . PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia. Blood. 2001; 98 (Suppl 1) 846a
27 O’Dwyer M E, Mauro M J, Kuyl J M, Paquette R, Sawyers C L, Druker B J. Preliminary evaluation of the combination of imatinib mesylate (Glevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML. Blood. 2001; 98 (Suppl 1) 846a
28 Okuda K, Weisberg E, Gilliland D G, Griffin J D. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001; 97 2440-2448
29 Ottmann O G, Sawyers C, Druker B, Goldman J, O’Brien S G, Reiffers J, Silver R T, Tura S, Fischer T, Niederwieser D, Schiffer C, Baccarani M, Gratwohl A, Hochhaus A, Reese S F, Capdeville R. Phase II study of STI571 in adult patients with Philadelphia chromosome (Ph) positive acute leukaemias. Hematol J. 2001; 2 (Suppl 1) 93
30 Rubin B P, Singer S, Tsao C, Duensing A, Lux M L, Ruiz R, Hibbard M K, Chen C J, Xiao S, Tuveson D A, Demetri G D, Fletcher D M, Fletcher J A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001; 61 8118-8121
31 Sawyers C L. Cancer treatment in the STI571 era: What will change?. J Clin Oncol. 2001; 19 (Suppl 1) 13s-16s
32 Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C, Ottmann O G, Schiffer C A, Talpaz M, Guilhot F, Niederwieser D, Ben-Am M, Gathmann I, Ford J, Druker B J. on behalf of the International Gleevec Study Group . Gleevec/Glivec (Imatinib mesylate, STI-571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: Updated results of a phase II study. Blood. 2001; 98 (Suppl 1) 845a
33 Silver R T, Woolf S H, Hehlmann R, Appelbaum F R, Anderson J, Bennett C, Goldman J M, Guilhot F, Kantarjian H M, Lichtin A E, Talpaz M, Tura S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood. 1999; 94 1517-1536
34 Talpaz M, Silver R T, Druker B, Paquette R, Goldman J M, G ambacorti-Passerini C, Guilhot F, Schiffer C A, Reese S F, Kantarjian H M, Ford J M. GleevecTM (formerly STI571): An active drug in patients with PH+ chronic myeloid leukemia in accelerated phase - updated results of a phase II study. Blood. 2001; 98 (Suppl 1) 845a
35 Thiesing J T, Ohno-Jones S, Kolibaba K S, Druker B J. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood. 2000; 96 3195-3199
36 Topaly J, Zeller W, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positivbe chronic myelogenous leukemia cells. Leukemia. 2001; 15 342-347
37 van Oosterom A T, Judson I, Verweij J, Stroobants S, di Paola E D, Dimitrijevic S, Martens M, Webb A, Sciot R, van Glabbeke M, Silberman S, Nielsen O S, for t he European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001; 358 1421-1423
38 Weisberg E, Griffin J D. Mechanism of resistence to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000; 95 3498-3505

Korrespondenz

Priv.-Doz. Dr. med. Andreas Hochhaus

III. Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg

Wiesbadener Straße 7-11

68305 Mannheim

Phone: 0621/3832854

Fax: 0621/3833833

Email: hochhaus@uni-hd.de